nodes	percent_of_prediction	percent_of_DWPC	metapath
Phenylbutazone—SLC22A11—Furosemide—dilated cardiomyopathy	0.469	0.503	CbGbCtD
Phenylbutazone—SLC22A8—Furosemide—dilated cardiomyopathy	0.273	0.293	CbGbCtD
Phenylbutazone—SLC22A6—Furosemide—dilated cardiomyopathy	0.19	0.204	CbGbCtD
Phenylbutazone—CYP2C9—cardial valve—dilated cardiomyopathy	0.0183	0.52	CbGeAlD
Phenylbutazone—PTGIS—myocardium—dilated cardiomyopathy	0.00706	0.2	CbGeAlD
Phenylbutazone—PTGIS—heart—dilated cardiomyopathy	0.00493	0.14	CbGeAlD
Phenylbutazone—Fosphenytoin—SCN5A—dilated cardiomyopathy	0.00487	0.562	CrCbGaD
Phenylbutazone—SLC22A11—Organic cation/anion/zwitterion transport—SLC22A5—dilated cardiomyopathy	0.00389	0.16	CbGpPWpGaD
Phenylbutazone—SLC22A8—Organic cation/anion/zwitterion transport—SLC22A5—dilated cardiomyopathy	0.00297	0.122	CbGpPWpGaD
Phenylbutazone—SLC22A6—Organic cation/anion/zwitterion transport—SLC22A5—dilated cardiomyopathy	0.00248	0.102	CbGpPWpGaD
Phenylbutazone—Phenytoin—SCN5A—dilated cardiomyopathy	0.00215	0.248	CrCbGaD
Phenylbutazone—PTGS1—myocardium—dilated cardiomyopathy	0.00132	0.0376	CbGeAlD
Phenylbutazone—CYP2C9—heart—dilated cardiomyopathy	0.00101	0.0287	CbGeAlD
Phenylbutazone—PTGS2—Synthesis of 15-eicosatetraenoic acid derivatives—GPX1—dilated cardiomyopathy	0.000984	0.0405	CbGpPWpGaD
Phenylbutazone—Diphenhydramine—SLC22A5—dilated cardiomyopathy	0.000971	0.112	CrCbGaD
Phenylbutazone—PTGS1—heart—dilated cardiomyopathy	0.000924	0.0262	CbGeAlD
Phenylbutazone—PTGS2—heart—dilated cardiomyopathy	0.000883	0.0251	CbGeAlD
Phenylbutazone—PTGS1—cardiac atrium—dilated cardiomyopathy	0.00079	0.0224	CbGeAlD
Phenylbutazone—SLC22A11—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A5—dilated cardiomyopathy	0.000779	0.0321	CbGpPWpGaD
Phenylbutazone—PTGIS—Arachidonic acid metabolism—GPX1—dilated cardiomyopathy	0.00074	0.0304	CbGpPWpGaD
Phenylbutazone—Phenoxybenzamine—ADRB2—dilated cardiomyopathy	0.000672	0.0776	CrCbGaD
Phenylbutazone—SLC22A8—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A5—dilated cardiomyopathy	0.000594	0.0244	CbGpPWpGaD
Phenylbutazone—PTGIS—Adipogenesis—LMNA—dilated cardiomyopathy	0.000552	0.0227	CbGpPWpGaD
Phenylbutazone—SLC22A6—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A5—dilated cardiomyopathy	0.000496	0.0204	CbGpPWpGaD
Phenylbutazone—PTGIS—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	0.000458	0.0188	CbGpPWpGaD
Phenylbutazone—PTGIS—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	0.00043	0.0177	CbGpPWpGaD
Phenylbutazone—PTGS2—S1P1 pathway—RAC1—dilated cardiomyopathy	0.000359	0.0148	CbGpPWpGaD
Phenylbutazone—SLC22A11—SLC-mediated transmembrane transport—SLC22A5—dilated cardiomyopathy	0.000354	0.0146	CbGpPWpGaD
Phenylbutazone—PTGIS—Adipogenesis—FAS—dilated cardiomyopathy	0.000322	0.0133	CbGpPWpGaD
Phenylbutazone—PTGIS—Adipogenesis—AGT—dilated cardiomyopathy	0.000302	0.0124	CbGpPWpGaD
Phenylbutazone—PTGS2—Calcium signaling in the CD4+ TCR pathway—FASLG—dilated cardiomyopathy	0.000271	0.0111	CbGpPWpGaD
Phenylbutazone—SLC22A8—SLC-mediated transmembrane transport—SLC22A5—dilated cardiomyopathy	0.00027	0.0111	CbGpPWpGaD
Phenylbutazone—PTGS1—Arachidonic acid metabolism—GPX1—dilated cardiomyopathy	0.000227	0.00935	CbGpPWpGaD
Phenylbutazone—SLC22A6—SLC-mediated transmembrane transport—SLC22A5—dilated cardiomyopathy	0.000225	0.00927	CbGpPWpGaD
Phenylbutazone—PTGIS—Metabolism—ANKRD1—dilated cardiomyopathy	0.000204	0.00838	CbGpPWpGaD
Phenylbutazone—PTGS1—Overview of nanoparticle effects—TNF—dilated cardiomyopathy	0.000196	0.00806	CbGpPWpGaD
Phenylbutazone—PTGIS—Metabolism—TAZ—dilated cardiomyopathy	0.000192	0.00788	CbGpPWpGaD
Phenylbutazone—PTGS2—Aryl Hydrocarbon Receptor—CD36—dilated cardiomyopathy	0.000188	0.00773	CbGpPWpGaD
Phenylbutazone—PTGS2—Integrated Pancreatic Cancer Pathway—PLN—dilated cardiomyopathy	0.000185	0.00762	CbGpPWpGaD
Phenylbutazone—SLC22A11—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	0.000185	0.00761	CbGpPWpGaD
Phenylbutazone—PTGS2—Arachidonic acid metabolism—GPX1—dilated cardiomyopathy	0.00018	0.00742	CbGpPWpGaD
Phenylbutazone—SLC22A11—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	0.00018	0.0074	CbGpPWpGaD
Phenylbutazone—SLC22A11—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	0.00018	0.0074	CbGpPWpGaD
Phenylbutazone—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—FASLG—dilated cardiomyopathy	0.000175	0.00721	CbGpPWpGaD
Phenylbutazone—PTGIS—Metabolism—SDHA—dilated cardiomyopathy	0.000173	0.00713	CbGpPWpGaD
Phenylbutazone—SLC22A11—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	0.000167	0.00688	CbGpPWpGaD
Phenylbutazone—PTGS2—Overview of nanoparticle effects—TNF—dilated cardiomyopathy	0.000156	0.0064	CbGpPWpGaD
Phenylbutazone—PTGS1—Selenium Micronutrient Network—SOD2—dilated cardiomyopathy	0.000152	0.00624	CbGpPWpGaD
Phenylbutazone—PTGS2—Spinal Cord Injury—CXCL2—dilated cardiomyopathy	0.000147	0.00605	CbGpPWpGaD
Phenylbutazone—PTGS1—Selenium Micronutrient Network—GPX1—dilated cardiomyopathy	0.000145	0.00595	CbGpPWpGaD
Phenylbutazone—SLC22A8—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	0.000141	0.0058	CbGpPWpGaD
Phenylbutazone—PTGS1—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	0.000141	0.00579	CbGpPWpGaD
Phenylbutazone—SLC22A8—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	0.000137	0.00565	CbGpPWpGaD
Phenylbutazone—SLC22A8—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	0.000137	0.00565	CbGpPWpGaD
Phenylbutazone—PTGIS—Adipogenesis—TNF—dilated cardiomyopathy	0.000137	0.00563	CbGpPWpGaD
Phenylbutazone—PTGS1—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	0.000132	0.00544	CbGpPWpGaD
Phenylbutazone—SLC22A8—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	0.000128	0.00525	CbGpPWpGaD
Phenylbutazone—PTGS2—Selenium Micronutrient Network—SOD2—dilated cardiomyopathy	0.00012	0.00495	CbGpPWpGaD
Phenylbutazone—CYP2C9—Arachidonic acid metabolism—GPX1—dilated cardiomyopathy	0.000119	0.00492	CbGpPWpGaD
Phenylbutazone—SLC22A6—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	0.000118	0.00484	CbGpPWpGaD
Phenylbutazone—PTGS2—Aryl Hydrocarbon Receptor—RAF1—dilated cardiomyopathy	0.000117	0.00483	CbGpPWpGaD
Phenylbutazone—PTGS2—Selenium Micronutrient Network—GPX1—dilated cardiomyopathy	0.000115	0.00472	CbGpPWpGaD
Phenylbutazone—SLC22A6—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	0.000115	0.00471	CbGpPWpGaD
Phenylbutazone—SLC22A6—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	0.000115	0.00471	CbGpPWpGaD
Phenylbutazone—PTGS2—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	0.000112	0.00459	CbGpPWpGaD
Phenylbutazone—PTGS2—Spinal Cord Injury—GJA1—dilated cardiomyopathy	0.000109	0.0045	CbGpPWpGaD
Phenylbutazone—SLC22A6—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	0.000106	0.00438	CbGpPWpGaD
Phenylbutazone—PTGIS—Disease—NPPA—dilated cardiomyopathy	0.000106	0.00436	CbGpPWpGaD
Phenylbutazone—PTGIS—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	0.000106	0.00435	CbGpPWpGaD
Phenylbutazone—PTGS2—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	0.000105	0.00432	CbGpPWpGaD
Phenylbutazone—PTGIS—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	0.000103	0.00423	CbGpPWpGaD
Phenylbutazone—PTGIS—Disease—PSEN2—dilated cardiomyopathy	0.000103	0.00422	CbGpPWpGaD
Phenylbutazone—PTGIS—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	9.27e-05	0.00381	CbGpPWpGaD
Phenylbutazone—PTGS2—Spinal Cord Injury—RAC1—dilated cardiomyopathy	8.33e-05	0.00343	CbGpPWpGaD
Phenylbutazone—PTGS2—Aryl Hydrocarbon Receptor—EGFR—dilated cardiomyopathy	8.05e-05	0.00331	CbGpPWpGaD
Phenylbutazone—PTGS2—Aryl Hydrocarbon Receptor—TNF—dilated cardiomyopathy	7.67e-05	0.00315	CbGpPWpGaD
Phenylbutazone—CYP2C9—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	7.39e-05	0.00304	CbGpPWpGaD
Phenylbutazone—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—dilated cardiomyopathy	7.17e-05	0.00295	CbGpPWpGaD
Phenylbutazone—CYP2C9—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	6.95e-05	0.00286	CbGpPWpGaD
Phenylbutazone—PTGS1—Metabolism—ANKRD1—dilated cardiomyopathy	6.26e-05	0.00258	CbGpPWpGaD
Phenylbutazone—PTGS2—Integrated Pancreatic Cancer Pathway—FASLG—dilated cardiomyopathy	6e-05	0.00247	CbGpPWpGaD
Phenylbutazone—PTGS1—Metabolism—TAZ—dilated cardiomyopathy	5.89e-05	0.00242	CbGpPWpGaD
Phenylbutazone—PTGS2—Integrated Pancreatic Cancer Pathway—FAS—dilated cardiomyopathy	5.78e-05	0.00238	CbGpPWpGaD
Phenylbutazone—PTGS1—Selenium Micronutrient Network—TNF—dilated cardiomyopathy	5.75e-05	0.00236	CbGpPWpGaD
Phenylbutazone—PTGS2—Integrated Pancreatic Cancer Pathway—RAC1—dilated cardiomyopathy	5.67e-05	0.00233	CbGpPWpGaD
Phenylbutazone—PTGS1—Metabolism—SDHA—dilated cardiomyopathy	5.33e-05	0.00219	CbGpPWpGaD
Phenylbutazone—PTGIS—Disease—RAC1—dilated cardiomyopathy	5.16e-05	0.00212	CbGpPWpGaD
Phenylbutazone—PTGS2—Metabolism—ANKRD1—dilated cardiomyopathy	4.97e-05	0.00205	CbGpPWpGaD
Phenylbutazone—PTGIS—Metabolism—GPX1—dilated cardiomyopathy	4.71e-05	0.00194	CbGpPWpGaD
Phenylbutazone—PTGS2—Metabolism—TAZ—dilated cardiomyopathy	4.68e-05	0.00192	CbGpPWpGaD
Phenylbutazone—PTGIS—Metabolism—CD36—dilated cardiomyopathy	4.58e-05	0.00189	CbGpPWpGaD
Phenylbutazone—PTGS2—Selenium Micronutrient Network—TNF—dilated cardiomyopathy	4.56e-05	0.00188	CbGpPWpGaD
Phenylbutazone—PTGS2—Metabolism—SDHA—dilated cardiomyopathy	4.23e-05	0.00174	CbGpPWpGaD
Phenylbutazone—PTGIS—Metabolism—AGT—dilated cardiomyopathy	4.13e-05	0.0017	CbGpPWpGaD
Phenylbutazone—PTGS2—Spinal Cord Injury—EGFR—dilated cardiomyopathy	3.79e-05	0.00156	CbGpPWpGaD
Phenylbutazone—PTGS2—Integrated Pancreatic Cancer Pathway—RAF1—dilated cardiomyopathy	3.76e-05	0.00155	CbGpPWpGaD
Phenylbutazone—SLC22A11—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	3.65e-05	0.0015	CbGpPWpGaD
Phenylbutazone—PTGS2—Spinal Cord Injury—TNF—dilated cardiomyopathy	3.61e-05	0.00148	CbGpPWpGaD
Phenylbutazone—PTGIS—Disease—RAF1—dilated cardiomyopathy	3.42e-05	0.00141	CbGpPWpGaD
Phenylbutazone—CYP2C9—Metabolism—ANKRD1—dilated cardiomyopathy	3.29e-05	0.00135	CbGpPWpGaD
Phenylbutazone—PTGS1—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	3.25e-05	0.00134	CbGpPWpGaD
Phenylbutazone—PTGS1—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	3.16e-05	0.0013	CbGpPWpGaD
Phenylbutazone—CYP2C9—Metabolism—TAZ—dilated cardiomyopathy	3.1e-05	0.00127	CbGpPWpGaD
Phenylbutazone—PTGS1—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	2.85e-05	0.00117	CbGpPWpGaD
Phenylbutazone—CYP2C9—Metabolism—SDHA—dilated cardiomyopathy	2.8e-05	0.00115	CbGpPWpGaD
Phenylbutazone—SLC22A8—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	2.78e-05	0.00114	CbGpPWpGaD
Phenylbutazone—PTGS2—Disease—NPPA—dilated cardiomyopathy	2.58e-05	0.00106	CbGpPWpGaD
Phenylbutazone—PTGS2—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	2.58e-05	0.00106	CbGpPWpGaD
Phenylbutazone—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—dilated cardiomyopathy	2.58e-05	0.00106	CbGpPWpGaD
Phenylbutazone—PTGS2—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	2.51e-05	0.00103	CbGpPWpGaD
Phenylbutazone—PTGS2—Disease—PSEN2—dilated cardiomyopathy	2.5e-05	0.00103	CbGpPWpGaD
Phenylbutazone—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—dilated cardiomyopathy	2.45e-05	0.00101	CbGpPWpGaD
Phenylbutazone—PTGIS—Disease—EGFR—dilated cardiomyopathy	2.35e-05	0.000965	CbGpPWpGaD
Phenylbutazone—SLC22A6—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	2.32e-05	0.000955	CbGpPWpGaD
Phenylbutazone—PTGS2—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	2.26e-05	0.00093	CbGpPWpGaD
Phenylbutazone—CYP3A4—Metabolism—ANKRD1—dilated cardiomyopathy	2.17e-05	0.000893	CbGpPWpGaD
Phenylbutazone—CYP3A4—Metabolism—TAZ—dilated cardiomyopathy	2.04e-05	0.00084	CbGpPWpGaD
Phenylbutazone—CYP3A4—Metabolism—SDHA—dilated cardiomyopathy	1.85e-05	0.00076	CbGpPWpGaD
Phenylbutazone—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	1.71e-05	0.000703	CbGpPWpGaD
Phenylbutazone—CYP2C9—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	1.66e-05	0.000684	CbGpPWpGaD
Phenylbutazone—CYP2C9—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	1.5e-05	0.000616	CbGpPWpGaD
Phenylbutazone—PTGS1—Metabolism—GPX1—dilated cardiomyopathy	1.45e-05	0.000595	CbGpPWpGaD
Phenylbutazone—PTGS1—Metabolism—CD36—dilated cardiomyopathy	1.41e-05	0.00058	CbGpPWpGaD
Phenylbutazone—PTGS1—Metabolism—AGT—dilated cardiomyopathy	1.27e-05	0.000522	CbGpPWpGaD
Phenylbutazone—PTGS2—Disease—RAC1—dilated cardiomyopathy	1.26e-05	0.000518	CbGpPWpGaD
Phenylbutazone—PTGS2—Metabolism—GPX1—dilated cardiomyopathy	1.15e-05	0.000472	CbGpPWpGaD
Phenylbutazone—PTGS2—Metabolism—CD36—dilated cardiomyopathy	1.12e-05	0.00046	CbGpPWpGaD
Phenylbutazone—PTGS2—Metabolism—AGT—dilated cardiomyopathy	1.01e-05	0.000414	CbGpPWpGaD
Phenylbutazone—PTGS2—Disease—RAF1—dilated cardiomyopathy	8.35e-06	0.000343	CbGpPWpGaD
Phenylbutazone—CYP2C9—Metabolism—GPX1—dilated cardiomyopathy	7.61e-06	0.000313	CbGpPWpGaD
Phenylbutazone—CYP2C9—Metabolism—CD36—dilated cardiomyopathy	7.41e-06	0.000305	CbGpPWpGaD
Phenylbutazone—CYP2C9—Metabolism—AGT—dilated cardiomyopathy	6.67e-06	0.000274	CbGpPWpGaD
Phenylbutazone—PTGS2—Disease—EGFR—dilated cardiomyopathy	5.72e-06	0.000235	CbGpPWpGaD
Phenylbutazone—CYP3A4—Metabolism—GPX1—dilated cardiomyopathy	5.02e-06	0.000206	CbGpPWpGaD
Phenylbutazone—CYP3A4—Metabolism—CD36—dilated cardiomyopathy	4.89e-06	0.000201	CbGpPWpGaD
Phenylbutazone—CYP3A4—Metabolism—AGT—dilated cardiomyopathy	4.4e-06	0.000181	CbGpPWpGaD
